S&P Futures
6,008.50 +2.00 (+0.03%) Dow Futures
44,825.00 -1.00 (-0.00%) Nasdaq Futures
20,894.50 +14.25 (+0.07%) Russell 2000 Futures
2,436.50 -14.50 (-0.59%) Crude Oil
69.59 +0.65 (+0.94%) Gold
2,630.50 +12.00 (+0.46%)
Altimmune, Inc. (ALT)
Pre-Market:
Altimmune, Inc.
910 Clopper Road
Suite 201S
Gaithersburg, MD 20878
United States
240 654 1450
https://altimmune.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 59
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Vipin K. Garg Ph.D. | President, CEO & Director | 986.14k | N/A | 1958 |
| Dr. Matthew Scott Harris AGAF, FCAP, M.D., MS | Chief Medical Officer | 681.81k | N/A | 1953 |
| Mr. Raymond M. Jordt M.B.A. | Chief Business Officer | 578.85k | N/A | 1973 |
| Mr. Gregory L. Weaver CPA, M.B.A. | Chief Financial Officer | N/A | N/A | 1956 |
| Mr. Andrew Shutterly M.S. | Principal Financial & Accounting Officer and Corporate Controller | N/A | N/A | 1988 |
| Mr. Bertrand Georges Ph.D. | Chief Technology Officer | N/A | N/A | N/A |
| Dr. M. Scot Roberts Ph.D. | Chief Scientific Officer | 599.25k | N/A | 1959 |
| Mr. Tony Blandin B.S. | Vice President of Quality & Compliance Management | N/A | N/A | N/A |
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Corporate Governance
Altimmune, Inc.’s ISS Governance QualityScore as of November 1, 2024 is 7. The pillar scores are Audit: 6; Board: 4; Shareholder Rights: 4; Compensation: 10.
